David Mankoff, MD
Dr. Mankoff uses state-of-the-art imaging technologies to better diagnose cancer and guide treatment.Patient Care Philosophy:
My philosophy is to enhance patient care using state-of-the-art imaging to better diagnose cancer and guide treatment. The goal is to make sure patients and oncologists have the information they need to make the best possible treatment choices for the patient.
Title
- Nuclear Medicine Specialist, Associate Professor, Radiology Department, University of Washington School of Medicine
Clinical Expertise
Nuclear Medicine, Thyroid cancer treatment
Education And Training
- University of Pennsylvania School of Medicine, 1988
- Residencies: University of Washington - Dept. of Medicine/Residency Internal Medicine, 1991-1992
- University of Washington - Dept. of Medicine/Residency Nuclear Medicine, 1992-1995
Clinical Trials
Dr. Mankoff is the SCCA lead investigator for the following clinical trials:
- Phase II Marker of Hormone Sensitivity (6590)
- FES Imaging in Response to Hormone Therapy (6357)
- PET (F-18) Bone Mets (6337)
- Early Assessment Challenge Grant (7043)